
James McCullough of RenalytixAI
February 1, 2021

BioUtah president & CEO Kelvyn Cullimore interviews RenalytixAI CEO James McCullough to discuss the growth and innovations of RenalytixAI, a diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs. Topics discussed include:
- Kidney diseases prognostics
- Alternate means of funding a life sciences company
- Life sciences companies locating in Utah
- Much more
James McCullough Bio:
James McCullough has served as our co-founder and Chief Executive Officer since our inception. Mr. McCullough has leadership experience building emerging technology companies in both the public and private sectors with specific expertise in the life-sciences industry. From 2008 to 2014, he served as chief executive officer of Exosome Diagnostics Inc., a venture backed personalized medicine company developing non-invasive liquid biopsy diagnostics in cancer that was acquired by Bio-Techne Corporation in 2018. Since 2014, Mr. McCullough has also served as a managing partner of Renwick Capital, LLC, a management consulting firm specializing in assisting emerging healthcare technology companies with strategic planning and business execution. He received his B.A. from Boston University and an MBA from Columbia Business School.Recent News
- BioUtah’s 2026 Utah Life Sciences Summit Recap
- 2026 Life Sciences Awards to be Presented at the Mayer Brown Utah Life Sciences Summit
- PROGRESS TRIAL DEMONSTRATES EDWARDS TAVR IS SUPERIOR TO CLINICAL SURVEILLANCE FOR MODERATE AS PATIENTS WITH AT-RISK FEATURES
- Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product














